A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety
Infectious Medicine,
Journal Year:
2023,
Volume and Issue:
2(4), P. 247 - 261
Published: Sept. 13, 2023
The
severe
acute
respiratory
syndrome
coronavirus
disease
2
instigated
by
of
2019
(COVID-19)
has
delivered
an
unfathomable
obstruction
that
touched
all
sectors
worldwide.
Despite
new
vaccine
technologies
and
mass
administration
booster
doses,
the
virus
persists,
unknown
ending
pandemic
for
variants
sub-variants.
Moreover,
whether
leaning
on
home
medications
or
using
plant
extracts
is
sufficient
often
to
combat
generated
tremendous
interest
in
scientific
fraternity.
Different
databases
including
PubMed,
Scopus,
Web
Science,
Google
Scholar
used
find
published
articles
linked
with
related
topics.
Currently,
COVID-19
third
fourth
shots
vaccines
are
progressively
administered
worldwide,
where
some
countries
trail
others
a
significant
margin.
Many
proteins
viral
activity
have
changed,
possibly
boosting
infectivity
making
antibodies
ineffective.
This
study
will
reminisce
genome,
associated
pathways
protein
functions,
variants,
their
mutations.
current,
comprehensive
review
also
provide
information
developed
several
biotech
companies
efficacy
costs
boosters
level.
As
no
working
protect
fully
against
proactive
research
needs
be
conducted
based
sub-lineage,
Language: Английский
Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus
Diseases,
Journal Year:
2023,
Volume and Issue:
11(4), P. 177 - 177
Published: Dec. 10, 2023
The
COVID-19
pandemic
has
had
a
profound
impact
on
societies,
public
health,
healthcare
systems,
and
the
world
economy.
With
over
771
million
people
infected
worldwide
staggering
death
toll
exceeding
6,960,783
as
of
4
October
2023
(according
to
World
Health
Organization),
urgency
for
solution
was
paramount.
Since
outbreak,
demand
immediate
treatment
viral
infection,
well
effective
vaccination
against
this
virus,
soaring,
which
led
scientists,
pharmaceutical/biotech
companies,
government
health
agencies,
etc.,
think
about
strategy
that
could
control
minimize
outbreak
soon
possible.
Vaccination
emerged
most
combat
infectious
disease.
For
strategies,
any
conventional
vaccine
approach
using
attenuated
live
or
inactivated/engineered
other
approaches,
typically
requires
years
research
assessment.
However,
situation
promoted
faster
more
development
COVID-19.
role
nanotechnology
in
designing,
manufacturing,
boosting,
delivering
vaccines
host
counter
virus
unquestionably
valued
assessed.
Several
nanoformulations
are
discussed
here
terms
their
composition,
physical
properties,
credibility,
applications
past
(as
possibility
those
used
previous
generation
vaccine).
Controlling
eliminating
spread
preventing
future
recurrence
safe,
tolerable,
strategy.
In
review,
we
discuss
potential
basis
an
Language: Английский
Development of semisynthetic saponin immunostimulants
Di Bai,
No information about this author
Hyun Jung Kim,
No information about this author
Pengfei Wang
No information about this author
et al.
Medicinal Chemistry Research,
Journal Year:
2024,
Volume and Issue:
33(8), P. 1292 - 1306
Published: May 18, 2024
Abstract
Many
natural
saponins
demonstrate
immunostimulatory
adjuvant
activities,
but
they
also
have
some
inherent
drawbacks
that
limit
their
clinical
use.
To
overcome
these
limitations,
extensive
structure-activity-relationship
(SAR)
studies
been
conducted.
The
SAR
of
QS-21
and
related
reveal
respective
fatty
side
chains
are
crucial
for
potentiating
a
strong
cellular
immune
response.
Replacing
the
hydrolytically
unstable
ester
chain
in
C28
oligosaccharide
domain
with
an
amide
same
or
C3
branched
trisaccharide
is
viable
approach
generating
robust
semisynthetic
saponin
immunostimulants.
Given
striking
resemblance
momordica
(MS)
I
II
to
deacylated
Quillaja
Saponaria
(QS)
(e.g.,
QS-17,
QS-18,
QS-21),
incorporating
into
more
sustainable
MS,
instead
QS
saponins,
led
discovery
MS-derived
adjuvants
VSA-1
VSA-2.
This
review
focuses
on
authors’
previous
work
MS
saponins.
Language: Английский
The Development of Epitope-Based Recombinant Protein Vaccines against SARS-CoV-2
Kanwal Khalid,
No information about this author
Hui Xuan Lim,
No information about this author
Jung Shan Hwang
No information about this author
et al.
The AAPS Journal,
Journal Year:
2024,
Volume and Issue:
26(5)
Published: Aug. 13, 2024
Language: Английский
Coronavirus spike protein-based vaccines. Vaccine delivery systems
Medicine in Drug Discovery,
Journal Year:
2024,
Volume and Issue:
unknown, P. 100198 - 100198
Published: Sept. 1, 2024
Language: Английский
COVID-19 Vaccines: Development, Efficacy, Safety, and Global Distribution
Pacific International Journal,
Journal Year:
2023,
Volume and Issue:
6(1), P. 153 - 157
Published: Sept. 23, 2023
The
COVID-19
pandemic,
caused
by
the
novel
coronavirus
SARS-CoV-2,
has
had
a
profound
impact
on
global
public
health,
healthcare
systems,
and
economies.
development
deployment
of
safe
effective
vaccines
have
been
critical
component
response
to
pandemic.
In
this
review,
we
provide
an
overview
vaccine
development,
including
various
platforms
used,
evaluation
efficacy
safety,
challenges
strategies
related
distribution
administration.
We
also
discuss
implications
emerging
SARS-CoV-2
variants
for
effectiveness
future
research
directions.
Language: Английский